Regulatory T Cells and Cancer: A Two-Sided Story

Immunological Investigations

Volumn 45, Issue 8, 2016, Pages 797-812

  Wang, Kepeng ^a   Vella, Anthony T ^a  

^a UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer immunotherapy; cytokines; inflammation; regulatory T cells

Indexed keywords

AUTOANTIGEN; INTERLEUKIN 10; INTERLEUKIN 35; TRANSFORMING GROWTH FACTOR BETA; CYTOKINE; IL2RA PROTEIN, HUMAN; INTERLEUKIN 2 RECEPTOR ALPHA; LYMPHOCYTE ANTIGEN RECEPTOR; TUMOR ANTIGEN;

CANCER GROWTH; CANCER IMMUNOLOGY; CELL TRANSFORMATION; CHRONIC INFLAMMATION; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; EPITHELIUM CELL; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; TISSUE SPECIFICITY; ADAPTIVE IMMUNITY; ANTIGEN PRESENTING CELL; CELL COMMUNICATION; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; INFLAMMATION; LYMPHOCYTE ACTIVATION; NEOPLASM; PATHOLOGY; PHAGOCYTE; SIGNAL TRANSDUCTION;

ADAPTIVE IMMUNITY; ANTIGEN-PRESENTING CELLS; ANTIGENS, NEOPLASM; CELL COMMUNICATION; CYTOKINES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INFLAMMATION; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LYMPHOCYTE ACTIVATION; NEOPLASMS; PHAGOCYTES; RECEPTORS, ANTIGEN, T-CELL; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, REGULATORY;

EID: 84992456220     PISSN: 08820139     EISSN: 15324311     Source Type: Journal    
DOI: 10.1080/08820139.2016.1197242     Document Type: Review

References (156)

1. R.J.Akhurst, R.Derynck, (2001). TGF-beta signaling in cancer–a double-edged sword. Trends Cell Biol, 11(11), S44S51.
2. S.Arico, S.Pattingre, C.Bauvy, et al. (2002). Celecoxib induces apoptosis by inhibiting 3-phosphoinositide-dependent protein kinase-1 activity in the human colon cancer HT-29 cell line. J Biol Chem, 277(31), 27613–27621.
3. N.Arpaia, C.Campbell, X.Fan, et al. (2013). Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature 504(7480), 451–455.
4. L.Attisano, J.L.Wrana (2002). Signal transduction by the TGF-beta superfamily. Science, 296(5573), 1646–1647.
5. H.S.Azzam, J.B.DeJarnette, K.Huang, et al. (2001). Fine tuning of TCR signaling by CD5. J Immunology, 166(9), 5464–5472.
6. F.Balkwill, A.Mantovani (2001). Inflammation and cancer:back to Virchow? Lancet, 357(9255), 539–545.
7. C.Becker, M.C.Fantini, C.Schramm, et al. (2004). TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity, 21(4), 491–501.
8. S.Beissert, T.Schwarz (1999). Mechanisms involved in ultraviolet light-induced immunosuppression. J Investig Dermatol Symp Proc, 4(1), 61–64.
9. C.L.Bennett, J.Christie, F.Ramsdell, et al. (2001). The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet, 27(1), 20–21.
10. D.J.Berg, N.Davidson, R.Kuhn, et al. (1996). Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses. J Clin Invest, 98(4), 1010–1020.
11. E.Bettelli, Y.Carrier, W.Gao, et al. (2006). Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature, 441(7090), 235–238.
12. N.A.Bhowmick, A.Chytil, D.Plieth, et al. (2004). TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science, 303(5659), 848–851.
13. N.A.Bhowmick, E.G.Neilson, H.L.Moses (2004). Stromal fibroblasts in cancer initiation and progression. Nature, 432(7015), 332–337.
14. J.Bollrath, T.J.Phesse, V.A.von Burstin, et al. (2009). gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell, 15(2), 91–102.
15. T.Bopp, C.Becker, M.Klein, et al. (2007). Cyclic adenosine monophosphate is a key component of regulatory T cell-mediated suppression. J Exp Med, 204(6), 1303–1310.
16. G.Borsellino, M.Kleinewietfeld, D.Di Mitri, et al. (2007). Expression of ectonucleotidase CD39 by Foxp3+ Treg cells:hydrolysis of extracellular ATP and immune suppression. Blood, 110(4), 1225–1232.
17. M.E.Brunkow, E.W.Jeffery, K.A.Hjerrild, et al. (2001). Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet, 27(1), 68–73.
18. M.A.Burchill, J.Yang, C.Vogtenhuber, et al. (2007). IL-2 receptor beta-dependent STAT5 activation is required for the development of Foxp3+ regulatory T cells. J Immunol, 178(1), 280–290.
19. A.Calon, E.Espinet, S.Palomo-Ponce, et al. (2012). Dependency of colorectal cancer on a TGF-beta-driven program in stromal cells for metastasis initiation. Cancer Cell, 22(5), 571–584.
20. J.D.Carter, G.M.Calabrese, M.Naganuma, U.Lorenz (2005). Deficiency of the Src homology region 2 domain-containing phosphatase 1 (SHP-1) causes enrichment of CD4+CD25+ regulatory T cells. J Immunol, 174(11), 6627–6638.
21. T.A.Chatila, F.Blaeser, N.Ho, et al. (2000). JM2, encoding a fork head-related protein, is mutated in X-linked autoimmunity-allergic disregulation syndrome. J Clin Invest, 106(12), R75–81.
22. A.Chaudhry, R.M.Samstein, P.Treuting, et al. (2011). Interleukin-10 signaling in regulatory T cells is required for suppression of Th17 cell-mediated inflammation. Immunity, 34(4), 566–578.
23. L.Chen, D.B.Flies (2013). Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol, 13(4), 227–242.
24. W.Chen, W.Jin, N.Hardegen, et al. (2003). Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med, 198(12), 1875–1886.
25. W.S.Chen, J.H.Liu, S.J.Wei, et al. (2003). Colon cancer cells with high invasive potential are susceptible to induction of apoptosis by a selective COX-2 inhibitor. Cancer Sci, 94(3), 253–258.
26. M.L.Cho, J.W.Kang, Y.M.Moon, et al. (2006). STAT3 and NF-kappaB signal pathway is required for IL-23-mediated IL-17 production in spontaneous arthritis animal model IL-1 receptor antagonist-deficient mice. J Immunol, 176(9), 5652–5661.
27. P.M.Choi, M.P.Zelig (1994). Similarity of colorectal cancer in Crohn’s disease and ulcerative colitis:implications for carcinogenesis and prevention. Gut, 35(7), 950–954.
28. L.W.Collison, C.J.Workman, T.T.Kuo, et al. (2007). The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature, 450(7169), 566–569.
29. P.Correa, L.W.Pickle, E.Fontham, et al. (1983). Passive smoking and lung cancer. Lancet, 2(8350), 595–597.
30. L.M.Coussens, Z.Werb (2002). Inflammation and cancer. Nature 420(6917), 860–867.
31. M.A.Curran, W.Montalvo, H.Yagita, J.P.Allison (2010). PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci USA, 107(9), 4275–4280.
32. T.Dasu, J.E.Qualls, H.Tuna, et al. (2008). CD5 plays an inhibitory role in the suppressive function of murine CD4(+) CD25(+) T(reg) cells. Immunol Lett, 119(1–2), 103–113.
33. N.J.Davidson, M.W.Leach, M.M.Fort, et al. (1996). T helper cell 1-type CD4+ T cells, but not B cells, mediate colitis in interleukin 10-deficient mice. J Exp Med, 184(1), 241–251.
34. M.M.Davis, P.J.Bjorkman (1988). T-cell antigen receptor genes and T-cell recognition. Nature, 334(6181), 395–402.
35. K.L.Dennis, Y.Wang, N.R.Blatner, et al. (2013). Adenomatous polyps are driven by microbe-instigated focal inflammation and are controlled by IL-10-producing T cells. Cancer Res, 73(19), 5905–5913.
36. R.Derynck, R.J.Akhurst, A.Balmain (2001). TGF-beta signaling in tumor suppression and cancer progression. Nat Genet, 29(2), 117–129.
37. K.E.de Visser, A.Eichten, L.M.Coussens (2006). Paradoxical roles of the immune system during cancer development. Nat Rev Cancer, 6(1), 24–37.
38. J.A.DiDonato, F.Mercurio, M.Karin (2012). NF-kappaB and the link between inflammation and cancer. Immunol Rev, 246(1), 379–400.
39. R.Doll (1993). Mortality from lung cancer in asbestos workers 1955. Br J Ind Med, 50(6), 485–490.
40. R.Doll, A.B.Hill (1956). Lung cancer and other causes of death in relation to smoking; a second report on the mortality of British doctors. Br Med J, 2(5001), 1071–1081.
41. G.P.Dunn, A.T.Bruce, H.Ikeda, et al. (2002). Cancer immunoediting:from immunosurveillance to tumor escape. Nat Immunol, 3(11), 991–998.
42. J.A.Eaden, K.R.Abrams, J.F.Mayberry (2001). The risk of colorectal cancer in ulcerative colitis:a meta-analysis. Gut, 48(4), 526–535.
43. A.Ekbom, C.Helmick, M.Zack, H.O.Adami (1990a). Increased risk of large-bowel cancer in Crohn’s disease with colonic involvement. Lancet, 336(8711), 357–359.
44. A.Ekbom, C.Helmick, M.Zack, H.O.Adami. (1990b). Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med, 323(18), 1228–1233.
45. E.Elinav, R.Nowarski, C.A.Thaiss, et al. (2013). Inflammation-induced cancer:crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer, 13(11), 759–771.
46. H.B.El-Serag (2012). Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology, 142(6), 1264–1273 e1261.
47. S.E.Erdman, T.Poutahidis, M.Tomczak, et al. (2003). CD4+ CD25+ regulatory T lymphocytes inhibit microbially induced colon cancer in Rag2-deficient mice. Am J Pathol, 162(2), 691–702.
48. S.E.Erdman, V.P.Rao, T.Poutahidis et al. (2003). CD4(+)CD25(+) regulatory lymphocytes require interleukin 10 to interrupt colon carcinogenesis in mice. Cancer Res, 63(18), 6042–6050.
49. S.E.Erdman, J.J.Sohn, V.P.Rao, et al. (2005). CD4+CD25+ regulatory lymphocytes induce regression of intestinal tumors in ApcMin/+ mice. Cancer Res, 65(10), 3998–4004.
50. EUROGAST Study Group. (1993). An international association between Helicobacter pylori infection and gastric cancer. The EUROGAST Study Group. Lancet 341(8857), 1359–1362.
51. Z.Fehervari, S.Sakaguchi (2004). Development and function of CD25+CD4+ regulatory T cells. Curr Opin Immunol, 16(2), 203–208.
52. D.F.Fiorentino, A.Zlotnik, T.R.Mosmann, et al. (1991). IL-10 inhibits cytokine production by activated macrophages. J Immunol, 147(11), 3815–3822.
53. D.F.Fiorentino, A.Zlotnik, P.Vieira, et al. (1991). IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J Immunol, 146(10), 3444–3451.
54. J.D.Fontenot, M.A.Gavin, A.Y.Rudensky (2003). Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol, 4(4), 330–336.
55. J.D.Fontenot, J.P.Rasmussen, M.A.Gavin, A.Y.Rudensky (2005). A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol, 6(11), 1142–1151.
56. R.H.Friedline, D.S.Brown, H.Nguyen, et al. (2009). CD4+ regulatory T cells require CTLA-4 for the maintenance of systemic tolerance. J Exp Med, 206(2), 421–434.
57. Y.Furusawa, Y.Obata, S.Fukuda, et al. (2013). Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature, 504(7480), 446–450.
58. Y.Gao, W.Yang, M.Pan, et al. (2003). Gamma delta T cells provide an early source of interferon gamma in tumor immunity. J Exp Med, 198(3), 433–442.
59. A.B.Glick (2012). The role of TGFbeta signaling in squamous cell cancer:Lessons from mouse models. J Skin Cancer, 2012, 249063.
60. C.Go, P.Li, X.J.Wang (1999). Blocking transforming growth factor beta signaling in transgenic epidermis accelerates chemical carcinogenesis:a mechanism associated with increased angiogenesis. Cancer Res, 59(12), 2861–2868.
61. M.V.Goldberg, C.G.Drake (2011). LAG-3 in cancer immunotherapy. Curr Top Microbiol Immunol, 344, 269–278.
62. D.C.Gondek, L.F.Lu, S.A.Quezada, et al. (2005). Cutting edge:contact-mediated suppression by CD4+CD25+ regulatory cells involves a granzyme B-dependent, perforin-independent mechanism. J Immunol, 174(4), 1783–1786.
63. E.Gounaris, N.R.Blatner, K.Dennis, et al. (2009). T-regulatory cells shift from a protective anti-inflammatory to a cancer-promoting proinflammatory phenotype in polyposis. Cancer Res, 69(13), 5490–5497.
64. W.M.Grady, L.L.Myeroff, S.E.Swinler, et al. (1999). Mutational inactivation of transforming growth factor beta receptor type II in microsatellite stable colon cancers. Cancer Res, 59(2), 320–324.
65. F.R.Greten, L.Eckmann, T.F.Greten, et al. (2004). IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell, 118(3), 285–296.
66. S.Grivennikov, E.Karin, J.Terzic, et al. (2009). IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell, 15(2), 103–113.
67. S.I.Grivennikov, F.R.Greten, M.Karin (2010). Immunity, inflammation, and cancer. Cell, 140(6), 883–899.
68. S.I.Grivennikov, M.Karin (2010). Dangerous liaisons:STAT3 and NF-kappaB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev, 21(1), 11–19.
69. S.I.Grivennikov, K.Wang, D.Mucida, et al. (2012). Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature, 491(7423), 254–258.
70. J.F.Grosso, C.C.Kelleher, T.J.Harris, et al. (2007). LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems. J Clin Invest, 117(11), 3383–3392.
71. D.Hanahan, R.A.Weinberg (2011). Hallmarks of cancer:the next generation. Cell, 144(5), 646–674.
72. G.He, M.Karin (2011). NF-kappaB and STAT3 - key players in liver inflammation and cancer. Cell Res, 21(1), 159–168.
73. C.H.Heldin, K.Miyazono, P.ten Dijke (1997). TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature, 390(6659), 465–471.
74. S.Hori, T.Nomura, S.Sakaguchi (2003). Control of regulatory T cell development by the transcription factor Foxp3. Science, 299(5609), 1057–1061.
75. C.S.Hsieh, Y.Liang, A.J.Tyznik, et al. (2004). Recognition of the peripheral self by naturally arising CD25+ CD4+ T cell receptors. Immunity, 21(2), 267–277.
76. C.T.Huang, C.J.Workman, D.Flies, et al. (2004). Role of LAG-3 in regulatory T cells. Immunity, 21(4), 503–513.
77. J.M.Hughes, H.Weill (1991). Asbestosis as a precursor of asbestos related lung cancer:results of a prospective mortality study. Br J Ind Med, 48(4), 229–233.
78. H.Ikeda, L.J.Old, R.D.Schreiber (2002). The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev, 13(2), 95–109.
79. S.Z.Josefowicz, L.F.Lu, A.Y.Rudensky (2012). Regulatory T cells:mechanisms of differentiation and function. Annu Rev Immunol, 30, 531–564.
80. R.Kalluri, M.Zeisberg (2006). Fibroblasts in cancer. Nat Rev Cancer, 6(5), 392–401.
81. D.H.Kaplan, V.Shankaran, A.S.Dighe, et al. (1998). Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA, 95(13), 7556–7561.
82. M.Karin (2006). NF-kappaB and cancer:Mechanisms and targets. Mol Carcinog, 45(6), 355–361.
83. M.Karin, F.R.Greten (2005) NF-kappaB:linking inflammation and immunity to cancer development and progression. Nat Rev Immunol, 5(10), 749–759.
84. N.Khansari, Y.Shakiba, M.Mahmoudi (2009). Chronic inflammation and oxidative stress as a major cause of age-related diseases and cancer. Recent Pat Inflamm Allergy Drug Discov, 3(1), 73–80.
85. R.Khattri, T.Cox, S.A.Yasayko, F.Ramsdell (2003). An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat Immunol, 4(4), 337–342.
86. J.M.Kim, J.P.Rasmussen, A.Y.Rudensky (2007). Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. Nat Immunol, 8(2), 191–197.
87. K.S.Kim, S.W.Hong, D.Han, et al. (2016). Dietary antigens limit mucosal immunity by inducing regulatory T cells in the small intestine. Science, 351(6275), 858–863.
88. D.Kimelman, M.Kirschner (1987). Synergistic induction of mesoderm by FGF and TGF-beta and the identification of an mRNA coding for FGF in the early Xenopus embryo. Cell, 51(5), 869–877.
89. L.Klein, B.Kyewski, P.M.Allen, K.A.Hogquist (2014). Positive and negative selection of the T cell repertoire:what thymocytes see (and don’t see). Nat Rev Immunol, 14(6), 377–391.
90. K.Kretschmer, I.Apostolou, D.Hawiger, et al. (2005). Inducing and expanding regulatory T cell populations by foreign antigen. Nat Immunol, 6(12), 1219–1227.
91. S.Lamouille, J.Xu, R.Derynck (2014). Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol, 15(3), 178–196.
92. J.L.Langowski, X.Zhang, L.Wu, et al. (2006). IL-23 promotes tumour incidence and growth. Nature, 442(7101), 461–465.
93. S.K.Lathrop, S.M.Bloom, S.M.Rao, et al. (2011). Peripheral education of the immune system by colonic commensal microbiota. Nature, 478(7368), 250–254.
94. A.Laurence, C.M.Tato, T.S.Davidson, et al. (2007). Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. Immunity, 26(3), 371–381.
95. D.J.Lenschow, T.L.Walunas, J.A.Bluestone (1996). CD28/B7 system of T cell costimulation. Annu Rev Immunol, 14, 233–258.
96. M.O.Li, Y.Y.Wan, R.A.Flavell (2007). T cell-produced transforming growth factor-beta1 controls T cell tolerance and regulates Th1- and Th17-cell differentiation. Immunity, 26(5), 579–591.
97. Y.Liu, P.Zhang, J.Li, et al. (2008). A critical function for TGF-beta signaling in the development of natural CD4+CD25+Foxp3+ regulatory T cells. Nat Immunol, 9(6), 632–640.
98. M.Long, S.G.Park, I.Strickland, et al. (2009). Nuclear factor-kappaB modulates regulatory T cell development by directly regulating expression of Foxp3 transcription factor. Immunity, 31(6), 921–931.
99. K.Loser, J.Apelt, M.Voskort, et al. (2007). IL-10 controls ultraviolet-induced carcinogenesis in mice. J Immunol, 179(1), 365–371.
100. S.L.Lu, H.Herrington, D.Reh, et al. (2006). Loss of transforming growth factor-beta type II receptor promotes metastatic head-and-neck squamous cell carcinoma. Genes Dev, 20(10), 1331–1342.
101. P.Y.Mantel, N.Ouaked, B.Ruckert, et al. (2006). Molecular mechanisms underlying FOXP3 induction in human T cells. J Immunol, 176(6), 3593–3602.
102. A.Mantovani, P.Allavena, A.Sica, F.Balkwill (2008). Cancer-related inflammation. Nature, 454(7203), 436–444.
103. S.Markowitz, J.Wang, L.Myeroff, et al. (1995). Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science, 268(5215), 1336–1338.
104. S.D.Markowitz, A.B.Roberts (1996). Tumor suppressor activity of the TGF-beta pathway in human cancers. Cytokine Growth Factor Rev, 7(1), 93–102.
105. J.Massague, Y.G.Chen (2000). Controlling TGF-beta signaling. Genes Dev, 14(6), 627–644.
106. I.Melero, D.M.Berman, M.A.Aznar, et al. (2015). Evolving synergistic combinations of targeted immunotherapies to combat cancer. Nat Rev Cancer, 15(8), 457–472.
107. P.Mittal, M.C.St Rose, X.Wang, et al. (2015). Tumor-unrelated CD4 T cell help augments CD134 plus CD137 dual costimulation tumor therapy. J Immunol, 195(12), 5816–5826.
108. K.W.Moore, R.de Waal Malefyt, R.L.Coffman, A.O’Garra (2001). Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol, 19, 683–765.
109. R.J.Moore, D.M.Owens, G.Stamp, et al. (1999). Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. Nat Med, 5(7), 828–831.
110. H.L.Moses, E.Y.Yang, J.A.Pietenpol (1990). TGF-beta stimulation and inhibition of cell proliferation:new mechanistic insights. Cell, 63(2), 245–247.
111. M.B.Nicholl, C.L.Ledgewood, X.Chen, et al. (2014). IL-35 promotes pancreas cancer growth through enhancement of proliferation and inhibition of apoptosis:evidence for a role as an autocrine growth factor. Cytokine, 70(2), 126–133.
112. J.Nishio, K.Honda (2012). Immunoregulation by the gut microbiota. Cell Mol Life Sci, 69(21), 3635–3650.
113. B.Oppmann, R.Lesley, B.Blom, et al. (2000). Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity, 13(5), 715–725.
114. M.Oshima, J.E.Dinchuk, S.L.Kargman, et al. (1996). Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell, 87(5), 803–809.
115. R.Pacholczyk, H.Ignatowicz, P.Kraj, L.Ignatowicz (2006). Origin and T cell receptor diversity of Foxp3+CD4+CD25+ T cells. Immunity, 25(2), 249–259.
116. D.M.Pardoll (2012). The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer, 12(4), 252–264.
117. J.J.Perez-Villar, G.S.Whitney, M.A.Bowen, et al. (1999). CD5 negatively regulates the T-cell antigen receptor signal transduction pathway:involvement of SH2-containing phosphotyrosine phosphatase SHP-1. Mol Cell Biol, 19(4), 2903–2912.
118. S.Rebouissou, M.Amessou, G.Couchy, et al. (2009). Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours. Nature, 457(7226), 200–204.
119. S.Reuter, S.C.Gupta, M.M.Chaturvedi, B.B.Aggarwal (2010). Oxidative stress, inflammation, and cancer:how are they linked? Free Radic Biol Med, 49(11), 1603–1616.
120. Y.P.Rubtsov, J.P.Rasmussen, E.Y.Chi, et al. (2008). Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces. Immunity, 28(4), 546–558.
121. S.Sakaguchi (2000). Regulatory T cells:key controllers of immunologic self-tolerance. Cell, 101(5), 455–458.
122. S.Sakaguchi, N.Sakaguchi, M.Asano, et al. (1995). Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol, 155(3), 1151–1164.
123. B.Salomon, D.J.Lenschow, L.Rhee, et al. (2000). B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity, 12(4), 431–440.
124. M.Schmidt-Supprian, J.Tian, E.P.Grant, et al. (2004). Differential dependence of CD4+CD25+ regulatory and natural killer-like T cells on signals leading to NF-kappaB activation. Proc Natl Acad Sci USA, 101(13), 4566–4571.
125. R.D.Schreiber, L.J.Old, M.J.Smyth (2011). Cancer immunoediting:integrating immunity’s roles in cancer suppression and promotion. Science, 331(6024), 1565–1570.
126. T.N.Schumacher, R.D.Schreiber (2015). Neoantigens in cancer immunotherapy. Science, 348(6230), 69–74.
127. R.H.Schwartz (2003). T cell anergy. Annu Rev Immunol, 21, 305–334.
128. M.J.Selby, J.J.Engelhardt, M.Quigley, et al. (2013). Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol Res, 1(1), 32–42.
129. G.Sen, G.Bikah, C.Venkataraman, S.Bondada (1999). Negative regulation of antigen receptor-mediated signaling by constitutive association of CD5 with the SHP-1 protein tyrosine phosphatase in B-1 B cells. Eur J Immunol, 29(10), 3319–3328.
130. R.L.Shattuck-Brandt, G.W.Varilek, A.Radhika, et al. (2000). Cyclooxygenase 2 expression is increased in the stroma of colon carcinomas from IL-10(−/−) mice. Gastroenterology, 118(2), 337–345.
131. A.Singh, A.Singh, S.J.Bauer, et al. (2016). Genetic deletion of TNFalpha inhibits ultraviolet radiation-induced development of cutaneous squamous cell carcinomas in PKCepsilon transgenic mice via inhibition of cell survival signals. Carcinogenesis, 37(1), 72–80.
132. T.K.Starr, S.C.Jameson, K.A.Hogquist (2003). Positive and negative selection of T cells. Annu Rev Immunol, 21, 139–176.
133. S.E.Street, E.Cretney, M.J.Smyth (2001). Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis. Blood, 97(1), 192–197.
134. J.B.Swann, M.J.Smyth (2007). Immune surveillance of tumors. J Clin Invest, 117(5), 1137–1146.
135. X.Tai, M.Cowan, L.Feigenbaum, A.Singer (2005). CD28 costimulation of developing thymocytes induces Foxp3 expression and regulatory T cell differentiation independently of interleukin 2. Nat Immunol, 6(2), 152–162.
136. K.Taniguchi, L.W.Wu, S.I.Grivennikov, et al. (2015). A gp130-Src-YAP module links inflammation to epithelial regeneration. Nature, 519(7541), 57–62.
137. J.P.Thiery (2003). Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol, 15(6), 740–746.
138. G.Trinchieri, S.Pflanz, R.A.Kastelein (2003). The IL-12 family of heterodimeric cytokines:new players in the regulation of T cell responses. Immunity, 19(5), 641–644.
139. M.E.Turnis, D.V.Sawant, A.L.Szymczak-Workman, et al. (2016). Interleukin-35 limits anti-tumor immunity. Immunity, 44(2), 316–329.
140. K.B.Vang, J.Yang, S.A.Mahmud, et al. (2008). IL-2, -7, and -15, but not thymic stromal lymphopoeitin, redundantly govern CD4+Foxp3+ regulatory T cell development. J Immunol, 181(5), 3285–3290.
141. M.D.Vesely, M.H.Kershaw, R.D.Schreiber, M.J.Smyth (2011). Natural innate and adaptive immunity to cancer. Annu Rev Immunol, 29, 235–271.
142. D.A.Vignali, L.W.Collison, C.J.Workman (2008). How regulatory T cells work. Nat Rev Immunol, 8(7), 523–532.
143. D.A.Vignali, V.K.Kuchroo (2012). IL-12 family cytokines:immunological playmakers. Nat Immunol, 13(8), 722–728.
144. C.Y.Wang, J.R.Eshleman, J.K.Willson, S.Markowitz (1995). Both transforming growth factor-beta and substrate release are inducers of apoptosis in a human colon adenoma cell line. Cancer Res, 55(21), 5101–5105.
145. K.Wang, M.Karin (2015). Tumor-elicited inflammation and colorectal cancer. Adv Cancer Res, 128, 173–196.
146. Z.Wang, J.Q.Liu, Z.Liu, et al. (2013). Tumor-derived IL-35 promotes tumor growth by enhancing myeloid cell accumulation and angiogenesis. J Immunol, 190(5), 2415–2423.
147. R.S.Wildin, S.Smyk-Pearson, A.H.Filipovich (2002). Clinical and molecular features of the immunodysregulation, polyendocrinopathy, enteropathy, X linked (IPEX) syndrome. J Med Genet, 39(8), 537–545.
148. L.M.Williams, A.Y.Rudensky (2007). Maintenance of the Foxp3-dependent developmental program in mature regulatory T cells requires continued expression of Foxp3. Nat Immunol, 8(3), 277–284.
149. K.Wing, Y.Onishi, P.Prieto-Martin, et al. (2008). CTLA-4 control over Foxp3+ regulatory T cell function. Science, 322(5899), 271–275.
150. J.Xu, S.Lamouille, R.Derynck (2009). TGF-beta-induced epithelial to mesenchymal transition. Cell Res, 19(2), 156–172.
151. X.Yang, J.J.Letterio, R.J.Lechleider, et al. (1999). Targeted disruption of SMAD3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF-beta. EMBO J, 18(5), 1280–1291.
152. H.Yu, R.Jove (2004). The STATs of cancer–new molecular targets come of age. Nat Rev Cancer, 4(2), 97–105.
153. H.Yu, M.Kortylewski, D.Pardoll (2007). Crosstalk between cancer and immune cells:role of STAT3 in the tumour microenvironment. Nat Rev Immunol, 7(1), 41–51.
154. N.Yusuf, T.H.Nasti, S.K.Katiyar, et al. (2008). Antagonistic roles of CD4+ and CD8+ T-cells in 7,12-dimethylbenz(a)anthracene cutaneous carcinogenesis. Cancer Res, 68(10), 3924–3930.
155. D.M.Zhao, A.M.Thornton, R.J.DiPaolo, E.M.Shevach (2006). Activated CD4+CD25+ T cells selectively kill B lymphocytes. Blood, 107(10), 3925–3932.
156. S.G.Zheng, J.H.Wang, J.D.Gray, et al. (2004). Natural and induced CD4+CD25+ cells educate CD4+CD25- cells to develop suppressive activity:The role of IL-2, TGF-beta, and IL-10. J Immunol, 172(9), 5213–5221.